Diametric Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Diametric Capital’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,157	Closed	-$85.7K	–	460
2023 Q1	$85.7K	Buy	+13,157	New	+$101K	0.04%	277

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Diametric Capital's SPRY Position: Q2 2023 in Review

Diametric Capital sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 13,157 shares — an estimated $85.7K sold.

Diametric Capital first reported a position in SPRY in Q1 2023 and held it in 1 quarter. The position peaked at $85.7K in Q1 2023. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

Diametric Capital reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Diametric Capital sold 13,157 ARS Pharmaceuticals shares in Q2 2023, an estimated $85.7K.
Diametric Capital first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Diametric Capital's ARS Pharmaceuticals position peaked at $85.7K in Q1 2023.
92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.